Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MATINAS BIOPHARMA HOLDINGS, INC.

(MTNB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Matinas BioPharma to Participate in 33rd Annual Piper Sandler Virtual Healthcare Conference

11/18/2021 | 07:01am EST

BEDMINSTER, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform delivery technology, has been invited to present a Company overview at the Piper Sandler 33rd Annual Virtual Healthcare Conference, being held November 29December 2, 2021. The Company will also host investor meetings during the conference.

The pre-recorded presentation will be available on the IR Calendar page of the Investors section of the Company’s website (www.matinasbiopharma.com) beginning at 10:00 a.m. ET on Monday, November 22, 2021. A webcast replay will be accessible for 90 days following the event.

As a reminder, Jerome D. Jabbour, Chief Executive Officer of Matinas, and other members of the Matinas leadership team will participate in a fireside chat as part of the B. Riley Fall 2021 Growth Biotech Best Ideas Series on Tuesday, November 23, 2021 at 12:30 p.m. ET. The fireside chat, “Applying Targeted Intracellular Drug Delivery with an Innovative Lipid Nano-Crystal Platform for Life Threatening Acute & Chronic Disease Settings,” will be moderated by Mayank Mamtani, Managing Director, Head of Healthcare Research and Senior Biotech Analyst at B. Riley.

A webcast of the Company’s B. Riley fireside chat will be available via the IR Calendar page of the Investors section of the Company’s website (www.matinasbiopharma.com). A webcast replay will be accessible for 90 days following the event.

About Matinas BioPharma

Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) delivery platform. The Company is developing its own internal portfolio of products as well as partnering with leading pharmaceutical companies to develop new formulations that take full advantage of the unique characteristics of the LNC platform.

Preclinical and clinical data have demonstrated that this novel technology can provide solutions to many of the complex challenges in achieving safe and effective intracellular delivery, for both small molecules and larger, more complex molecules, such as mRNA, DNA plasmids, antisense oligonucleotides and vaccines. The combination of a unique mechanism of action and flexibility in both the formulation and route of administration (including oral), position Matinas’ LNC technology to potentially become the preferred next-generation intracellular drug delivery vehicle and an important improvement over both lipid nanoparticles and viral vectors.

MAT2203 is an oral, LNC formulation of the highly effective, but also highly toxic, antifungal medicine amphotericin B, primarily used as a first-line treatment for invasive fungal infections. MAT2203 is currently in a Phase 2 open-label, sequential cohort study (EnACT) in HIV-infected patients with cryptococcal meningitis. Enrollment in Cohort 3 of EnACT commenced following unanimous approval from the Data and Safety Monitoring Board (DSMB) and is now fully enrolled. DSMB evaluation of Cohort 3 data and potential cohort progression is expected in the fourth quarter of 2021.

MAT2501 is an oral, LNC formulation of the broad-spectrum aminoglycoside antibiotic amikacin, primarily used to treat chronic and acute bacterial infections. With the support of the Cystic Fibrosis Foundation, MAT2501 is currently undergoing important preclinical studies and commenced a Phase 1 human clinical trial in the fourth quarter of 2021. MAT2501 would be the first and only oral aminoglycoside, and is being positioned with an initial indication for the treatment of nontuberculous mycobacterial (NTM) lung disease, including infections in patients with cystic fibrosis.

LYPDISO™, is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, intended for the treatment of cardiovascular and metabolic conditions. This next-generation omega-3 therapy has been shown in two head-to-head studies to provide effective triglyceride-lowering and significantly higher EPA blood levels than Vascepa®. The Company has initiated a process to identity and potentially secure a partner to continue development of LYPDISO.    

Forward Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to our business activities, our strategy and plans, the potential of our LNC platform delivery technology, and the future development of its product candidates, including MAT2203, MAT2501, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the anticipated timing of regulatory interactions, the Company’s ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company’s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company’s products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma’s product candidates are all in a development stage and are not available for sale or use.

Investor and Media Contacts

Peter Vozzo
ICR Westwicke
443-213-0505
peter.vozzo@westwicke.com

Source: Matinas BioPharma Holdings, Inc.


Primary Logo

Source: Matinas BioPharma Holdings, Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about MATINAS BIOPHARMA HOLDINGS, INC.
01/18Matinas BioPharma to Provide Corporate Update and 2022 Business Outlook on January 25, ..
AQ
2021Matinas BioPharma Says Data Monitoring Panel Backs Continuation of Meningitis Trial to ..
MT
2021MATINAS BIOPHARMA : Announces Unanimous DSMB Approval to Progress into Fourth and Final Co..
PU
2021MATINAS BIOPHARMA HOLDINGS, INC. : Regulation FD Disclosure, Other Events, Financial State..
AQ
2021Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Fourth and Final C..
GL
2021Matinas Biopharma Announces Unanimous Dsmb Approval to Progress into Fourth and Final C..
CI
2021Matinas BioPharma Holdings Names Chief Business Officer
MT
2021MATINAS BIOPHARMA : Appoints Thomas Hoover, M.B.A. as Chief Business Officer - Form 8-K
PU
2021MATINAS BIOPHARMA HOLDINGS, INC. : Change in Directors or Principal Officers, Regulation F..
AQ
2021Matinas BioPharma Appoints Thomas Hoover, M.B.A. as Chief Business Officer
GL
More news
Analyst Recommendations on MATINAS BIOPHARMA HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2021 0,47 M - -
Net income 2021 -23,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,81x
Yield 2021 -
Capitalization 173 M 173 M -
Capi. / Sales 2021 366x
Capi. / Sales 2022 43,3x
Nbr of Employees 20
Free-Float 96,0%
Chart MATINAS BIOPHARMA HOLDINGS, INC.
Duration : Period :
Matinas BioPharma Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 0,80 $
Average target price 2,75 $
Spread / Average Target 244%
EPS Revisions
Managers and Directors
Jerome D. Jabbour President, Chief Executive Officer & Director
Keith A. Kucinski Chief Financial Officer
Herbert J. Conrad Chairman
Raphael J. Mannino Chief Scientific Officer & Senior Vice President
James J. Ferguson Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MATINAS BIOPHARMA HOLDINGS, INC.-18.81%173
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508